- Advertisement -

Nanoparticles in Biotechnology and Pharmaceuticals Market Increasing Demand with Leading Player, Comprehensive Analysis and Forecast 2026 – Science In Me

ShireThe competitive landscape of the Nanoparticles in Biotechnology and Pharmaceuticals market is examined in detail in the report, with a focus on the latest...

One in five Colorado high school students has access to firearms

New study looks at gun access among adolescents in Colorado Credit: CU Anschutz Medical Camppus Twenty percent of...

From Junk to Treasure: Syros Pharmaceuticals Mines Non-Coding DNA to Treat Disease

Syros is advancing a robust clinical-stage pipeline that includes: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and...

New workflow identifies hidden genetic connections that could improve personalized medicine...

All humans carry genetic variations in their DNA, called Single Nucleotide Polymorphisms (SNPs) that can underlie susceptibility to diseases such as diabetes and cancer....

Evonik invests in biotechnology startup In Ovo, supporting egg-industry reform –...

By Mary Page Bailey | March 29, 2021 <!-- --> <!----> Evonik Industries AG (Essen, Germany) has made a follow-up investment in...

Researchers discover new active substance effective against gram negative bacteria

More and more bacterial pathogens of infectious diseases become resistant to customary antibiotics. Typical hospital germs such as Escherichia coli and Klebsiella pneumoniae have...

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney...

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat...

Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for...

T cells are some of the immune system’s most important fighters. They can stop tumor growth and fight off severe infections. Scientists at La...

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat...

Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for Measles, Nipah Virus

T cells are some of the immune system’s most important fighters. They can stop tumor growth and fight off severe infections. Scientists at La...

Turning the Patent Cliff into a Bioplant Opportunity

The 2030 patent cliff may either decimate revenue streams or provide an opportunity for innovation that can transform the biopharmaceutical industry. As it stands...

more new items

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney...

Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat...

Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for...

T cells are some of the immune system’s most important fighters. They can stop tumor growth and fight off severe infections. Scientists at La...

Turning the Patent Cliff into a Bioplant Opportunity

The 2030 patent cliff may either decimate revenue streams or provide an opportunity for innovation that can transform the biopharmaceutical industry. As it stands...